Overview and Scope
Rotavirus prophylaxis refers to the prevention of rotavirus infection through vaccination, which protects infants and young children from a highly infectious illness that causes stomach and bowel inflammation. The purpose is to protect from person from any severity.
Sizing and Forecast
The rotavirus prophylaxis market size has grown rapidly in recent years. It will grow from $8.15 billion in 2023 to $9.05 billion in 2024 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to vaccine access and equity, emerging rotavirus strains, r&d investments, public health preparedness.
The rotavirus prophylaxis market size is expected to see strong growth in the next few years. It will grow to $13.24 billion in 2028 at a compound annual growth rate (CAGR) of 10.0%. The growth in the forecast period can be attributed to gastrointestinal disease burden, global expansion, vaccination programs, vaccine confidence. Major trends in the forecast period include next-generation vaccines, combination vaccines, vaccine delivery innovation, global immunization collaboration.
To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/rotavirus-prophylaxis-global-market-report
Segmentation & Regional Insights
The rotavirus prophylaxis market covered in this report is segmented –
1) By Treatment: Rotarix; Rotavac; Rotavin-M1; Oral Rehydration Fluid; Other Treatments
2) By Route of Administration: Oral; Parenteral; Other Route of Administrations
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy; Other Distribution Channels
4) By End-Users: Hospitals; Specialty Clinics; Homecare; Other End-Users
North America was the largest region in the rotavirus prophylaxis market in 2023. The regions covered in rotavirus prophylaxis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=13045&type=smp
Major Driver Impacting Market Growth
The increasing vaccine courses are expected to propel the growth of the rotavirus prophylaxis market going forward. A vaccine course is a specific dose of vaccine that is meant to be given to a person to produce protection from a particular disease. The vaccine course dosage stimulates the immunological response, providing excellent protection against rotavirus infection. This increased immunity minimizes the risk of diseases and improves the vaccine’s overall efficacy. For instance, in January 2022, according to a report published by the United Nations International Children’s Emergency Fund (UNICEF), a US-based provider of humanitarian and developmental help to children, around 5.71 million courses of RV1-5 frozen rotavirus vaccine were produced 2022, with a projected increase to 9.31 million courses by 2028. Furthermore, 5.29 million courses of RV5-2 lyophilized rotavirus vaccines were manufactured in 2022, with a projected rise to 6.13 million courses by 2028. Therefore, the increasing number of vaccines will drive the rotavirus prophylaxis market.
Key Industry Players
Major players in the rotavirus prophylaxis market are Pfizer Inc., Johnson & Johnson, Merck & Co., Novartis AG, Sanofi SA, Astra Zeneca Pharmaceuticals LP, GlaxoSmithKline PLC, Takeda Pharmaceutical Company Limited, Sinovac Biotech Ltd., Astellas Pharma Inc., CSL Limited, Bharat Biotech International Limited, Daiichi Sankyo Co. Ltd., Lupin Limited, Mitsubishi Tanabe Pharma Corporation, Serum Institute of India Pvt. Ltd., Zydus Lifescience Ltd., Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Biocad Biopharmaceutical Co., Bharat Serums and Vaccines Limited, Biological E Limited, PT Bio Farma, Panacea Biotec Ltd., Shanghai Institute of Biological Products (SIBP).
The rotavirus prophylaxis market report table of contents includes:
1. Executive Summary
2. Rotavirus Prophylaxis Market Characteristics
3. Rotavirus Prophylaxis Market Trends And Strategies
4. Rotavirus Prophylaxis Market – Macro Economic Scenario
5. Global Rotavirus Prophylaxis Market Size and Growth
.
.
.
26. South America Rotavirus Prophylaxis Market
27. Brazil Rotavirus Prophylaxis Market
28. Middle East Rotavirus Prophylaxis Market
29. Africa Rotavirus Prophylaxis Market
30. Rotavirus Prophylaxis Market Competitive Landscape And Company Profiles
Top Major Players:
- Pfizer Inc
- Johnson & Johnson
- Merck & Co
- Novartis AG
- Sanofi SA
Explore the trending research reports from TBRC:
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
